NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is a micro-cap medtech innovator currently trading at sa compelling valuation, with a market cap of approximately $30 million. Specializing in minimally invasive diagnostic and therapeutic devices, NMTC focuses primarily on neurological disorders, especially epilepsy—a massive, underserved, and chronic market. Its flagship innovation, the OneRF Ablation System, is the only FDA-cleared sEEG-guided radiofrequency ablation (RF) platform, offering both diagnostic and therapeutic utility:
Thanks for reading! Subscribe for free to receive new posts and support my work.
The stock is trading at depressed levels due to short-term headwinds: (1) a broad-market selloff on April 3rd linked to tariff concerns, and (2) a recent $7 million equity raise(on April 3rd). These events, while ostensibly negative, provide an asymmetric opportunity for investors willing to look through temporary volatility.
The OneRF system is a major part of NMTC’s portfolio, since it is the only FDA-cleared sEEG-RF system:
This is used to manage and handle epilepsy attacks better, and diagnose the actual origin of the attacks in the brain as well.
Needless to say it possesses remarkable technology with a big TAM, since epilepsy is one of the most common neurological-related diseases(About 3 million Americans at the moment!)
Why does this opportunity exist?
Despite the breakthrough nature of its technology, NMTC’s stock has come under significant pressure in recent weeks, creating what we view as an asymmetric opportunity. The recent decline was triggered by two primary catalysts. First, on April 3rd, macroeconomic fears surrounding tariff implementations led to a broad-based market selloff, impacting even companies with no international exposure:
Second, NMTC executed a $7 million equity raise, diluting existing shareholders. While the market reacted negatively to these events, a deeper dive reveals that neither has any bearing on NMTC’s long-term fundamentals.
Executive Summary:
Zimmer Biomet signed an exclusive distribution deal for NMTC’s FDA-cleared OneRF Ablation System, paying $3M upfront with potential for $1M in milestones. Zimmer ‘picked’ NMTC’s product to market and distribute
Product revenue tripled year-over-year, growing from $0.9M to $3.2M — before Zimmer’s commercial rollout began. Ask yourselves: what will be the impact afterZimmer clusters the platform with the portfolio?
Recent capital raise and Zimmer payment extend NMTC’s cash runway through FY 2026, resolving prior liquidity concerns.
No tariff exposure — all suppliers are U.S.-based, and NMTC has confirmed no overseas shipping activity.
A Fox News segment spotlighted a patient going from 10 nightly seizures to zero using NMTC’s device — underscoring clinical impact and market potential.
NMCT’s President, CEO, and CFO together have bought about 0.5% of NMCT’s market cap in the open market
The market is poised to grow, giving NMCT a huge growth runway
NMCT’s product has a first-mover advantage, and has other advantages over the products, bolstering our confidence in its growth potential
Theses:
The thesis boils down to the following points:
NMTC’s device has been ‘picked’ by Zimmer Biomet. Zimmer, a reputable company, has bought the license to market and sell the OneRF ablation system, which should spur future growth. As stated in NMTC’s financial statement(Q1 2025): ‘On October 25, 2024, the Company entered into the Zimmer Amended and Restated Distribution Agreement (the “Amendment”) with Zimmer pursuant to which the Company granted Zimmer the exclusive right and license to distribute its OneRF Ablation System for an upfront payment of $3.0 million, with eligibility for an additional $1.0 million payment from Zimmer upon achievement of certain specified net sales milestones.’ The strategic partnership with Zimmer Biomet, a $20 billion medtech co., also represents a critical vote of confidence in NMTC’s technology and its potential to scale. Under the revised agreement signed in October 2024, Zimmer received exclusive rights to distribute the OneRF System in exchange for the upfront cash and a potential additional milestone-based payment. Zimmer’s proven commercial infrastructure and global reach offer NMTC a far more efficient pathway to market than it could achieve independently.
NMTC’s quarterly product revenue(revenue from selling products unrelated to Zimmer’s license revenue) has grown more than 3-fold from last year Now, separate to its agreement with Zimmer Biomet, NMTC’s products have been gaining increased traction externally. Here are the results from its most recent 10-Q:
In terms of financial performance, NMTC is also showing signs of real traction. Excluding the Zimmer upfront revenue, organic product revenue for Q1 2025 exceeded $3.2 million, more than tripling from $0.9 million in the same quarter of the previous year. This surge in organic sales indicates increasing acceptance of NMTC’s devices within the neurology community and lays a strong foundation for Zimmer to build upon in future quarters.
Thus, we ask readers to consider the following: The product revenue(total revenue - license upfront payment) jumped to 3.2 million from 0.97 million from the year prior. How much more growth is in store for NMCT after Zimmer fully integrates the OneRF system into its portfolio:
NMTC, in the letter to shareholders, has revealed after the most recent capital raise and the upfront payments from zimmer for the ONeRF system license, it has secured enough capital for it to last through the end of FY 2026
According to the same shareholder letter above:
The capital raise, far from being a negative signal, has materially strengthened the company’s balance sheet. Along with a $3 million upfront payment from Zimmer Biomet—its newly signed exclusive distributor—NMTC now has sufficient liquidity to operate through the end of fiscal year 2026. This marks a significant improvement from earlier financial statements that questioned whether NMTC could sustain operations beyond April 2025:
There will be no tariff impact to NMTC whatsoever: In fact, NMTC has no overseas supply chain exposure whatsoever—all key components and manufacturing are sourced domestically within the U.S., a fact explicitly confirmed in a letter to shareholders, NMTC clarified to investors that they have no tariff exposure whatsoever, since all their suppliers are housed in the United States. All of they key components are sourced and manufactured in the US:
NMTC’s success story has been featured on Fox news, detailing the story of a girl who went from 10 nightly seizures to 0, with the help of NMTC’s device
Just about 10 days ago, NMTC’s OneRF ablation device was featured in Fox news due to it helping a teenager go from ‘10 nightly seizures to 0’:
The best part is the patient is now completely seizure-free:
Further underscoring the clinical potential of NMTC’s product is the public attention it has garnered. Just over a week ago, a Fox News segment detailed the story of a teenage girl who experienced a dramatic reduction in seizure frequency—from ten nightly episodes to none—after being treated with the OneRF system. This story, while anecdotal, provides compelling human validation of the device’s effectiveness and reinforces its unique position in the therapeutic landscape. NMTC is not just developing technology—it is changing lives, and stories like this one will likely help raise awareness and adoption over time.
NMCT’s President, CEO, and CFO together have bought about 0.5% of NMCT’s market cap in the open market: In a strong vote of confidence, NeuroOne Medical Technologies' President, CEO, and CFO have collectively purchased approximately 0.5% of the company’s total market capitalization in the open market just about 2-3 weeks ago:
Insider buying at this scale—particularly from top executive leadership—sends a powerful signal to investors. It reflects management’s conviction in the company’s long-term prospects and their belief that the current share price significantly undervalues NMTC’s true potential. This alignment of interests between executives and shareholders is especially meaningful for a micro-cap company, where leadership plays a critical role in execution, capital allocation, and investor trust. Such open-market purchases serve as a tangible indicator that those closest to the company’s operations view the recent selloff as a mispricing, not a reflection of deteriorating fundamentals.
.
Market Analysis of Epilepsy
According to a 2024 report by GlobeNewswire (Custom Market Insights), the global epilepsy treatment devices market was valued at approximately USD 526.8 million in 2023 and is projected to reach USD 548.4 million in 2024. By 2033, it is expected to grow to around USD 787.3 million, representing a compound annual growth rate (CAGR) of 4.1% from 2024 to 2033. Key drivers of this growth include advancements in neurostimulation technologies such as Vagus Nerve Stimulation (VNS), Responsive Neurostimulation (RNS), and Deep Brain Stimulation (DBS). These developments involve improvements in electrode design, stimulation algorithms, and integration with advanced imaging and monitoring systems. Additionally, the aging population, improved diagnostics, government initiatives, and a trend toward minimally invasive surgical procedures are propelling demand.
Product Analysis
NeuroOne’s flagship offering, the OneRF™ Ablation System, holds a unique position in the epilepsy treatment market as the only FDA-cleared sEEG-guided radiofrequency (RF) platform that offers both diagnostic and therapeutic capabilities through a single electrode. This technological integration allows for streamlined procedures, which can reduce the number of surgeries required, shorten hospital stays, and even enable bedside ablations. The Evo sEEG and Evo cortical electrode platforms, which are also FDA-cleared, feature thin-film, high-resolution designs that aim to minimize immunological responses and improve signal quality. These electrodes have demonstrated clear benefits in clinical settings, such as at the Mayo Clinic, where they were used successfully for epilepsy mapping and cortical recordings. The thin, flexible design has been praised for conforming securely to the brain surface, reducing trauma, and producing high-fidelity recordings. NeuroOne is also developing new RF ablation systems, including a device for trigeminal neuralgia, with a 510(k) submission planned for early 2025. (BioSpace, 2020–2023; Yahoo Finance, 2021; AInvest, 2025)
Growth Potential
Although NeuroOne Medical Technologies Corp. (NMTC) currently represents a small portion of the epilepsy device market, its projected FY2025 product revenue of $8–10 million would equate to approximately 1.5–1.8% market share based on current figures. The potential for growth is underscored by its FDA-cleared OneRF system, which offers a first-mover advantage in sEEG-guided ablation. Through its exclusive distribution agreement with Zimmer Biomet—a globally recognized MedTech firm—NeuroOne gains access to a well-established sales network, which could accelerate hospital adoption. The company’s long-term outlook also includes expansion into additional indications and markets, such as trigeminal neuralgia and chronic pain, using its proprietary electrode technology.
If NeuroOne successfully penetrates the 200+ Level 4 epilepsy centers in the U.S., it could see significant revenue gains. For example, if 100 centers adopted the system and conducted 10 procedures annually at $10,000–$20,000 per procedure, annual revenues could range between $10–20 million. That alone would push NMTC’s market share toward 2–4% in the total epilepsy device space. With ongoing clinical validation—evidenced by over 90% seizure reduction in treated patients—and new CMS reimbursement codes supporting its usage, the company is well-positioned for broader adoption. (AInvest, 2025; GlobeNewswire, 2024)
Mayo Clinic Connection
NeuroOne has had a longstanding collaborative and financial relationship with Mayo Clinic. The Evo cortical electrode and the Evo sEEG electrode technologies were both co-developed with Mayo Clinic and other academic institutions, including the Wisconsin Alumni Research Foundation (WARF). Mayo Clinic was not only involved in the early development of these platforms but also performed the first human commercial use of the Evo cortical electrode in December 2020 and the first clinical case using the Evo sEEG electrode in May 2023. Both procedures were conducted by Dr. Jamie Van Gompel, a noted neurosurgeon and co-developer of the technology, who praised the products for their thin-film design, secure brain conformance, and high-quality recordings.
In addition to its clinical role, Mayo Clinic made a financial investment in NeuroOne during Q2 2021, acquiring 181,754 shares at an average price of $7.01. This stake represented approximately 1.33% of Mayo’s investment portfolio at the time. Furthermore, Mayo Clinic and Dr. Van Gompel maintain financial interests in the technology, and any revenue received supports the institution’s non-profit mission. (BioSpace, 2020 & 2023; Yahoo Finance, 2021)
Conclusion
Conclusion
NeuroOne Medical Technologies Corp. (NMTC) represents a compelling asymmetric investment opportunity in the medtech space, particularly within the underpenetrated and growing epilepsy treatment device market. Backed by a highly differentiated product—the OneRF™ Ablation System—which uniquely combines diagnostic and therapeutic capabilities in a single, FDA-cleared platform, NMTC is well-positioned to capture share from a $500M+ global market projected to grow at a 4.1% CAGR.
The company’s recent momentum is underpinned by accelerating product revenue, strong clinical outcomes (over 90% seizure reduction in treated patients), and a transformative commercial partnership with Zimmer Biomet, one of the largest players in the global medical device industry. With Zimmer’s infrastructure now driving distribution, NMTC is poised for scalable growth, and its $3.2M in organic Q1 product revenue—before full Zimmer rollout—demonstrates significant early traction. Additional tailwinds include a newly issued CMS reimbursement code, potential expansion into other neurology indications like trigeminal neuralgia, and an extended cash runway through FY 2026 following a recent capital raise.
Beyond financials, NMTC’s credibility is bolstered by its longstanding relationship with Mayo Clinic, which not only co-developed its core technology but also became an early clinical adopter and financial backer. Insider buying by executive leadership further signals internal conviction in the company’s future prospects. Moreover, media attention, such as a Fox News story detailing a patient’s transformation from nightly seizures to complete seizure freedom using OneRF, reinforces the technology’s life-changing impact.
While risks remain—such as execution dependence on Zimmer Biomet, ongoing regulatory hurdles, and limited cash reserves—these are counterbalanced by the company’s unique IP, expanding product portfolio, improving financials, and strong strategic positioning. For investors with a high-risk tolerance and a long-term view, NMTC offers a rare combination of breakthrough technology, clinical validation, and early commercial momentum at a deeply discounted valuation. This makes it a “Buy” in our view.
Thanks for reading! Subscribe for free to receive new posts and support my work.
The most likely question worth looking further into for an activist investor is from category 2: "Is management destroying value through poor capital allocation?" specifically the sub-question "Are they issuing equity at depressed prices?" This stands out because the post highlights a recent dilutive equity raise at depressed stock levels as a key pressure point, which could signal value destruction in a nano-cap where capital decisions have outsized impact, even if the write-up frames it positively for liquidity.
Hi there, thanks for the great write up! I saw you mentioned "NMTC executed a $7 million equity raise, diluting existing shareholders" and was wondering if this could indicate management issuing equity at unduly depressed prices, potentially destroying shareholder value through poor capital allocation.
The most likely question worth looking further into for an activist investor is from category 2: "Is management destroying value through poor capital allocation?" specifically the sub-question "Are they issuing equity at depressed prices?" This stands out because the post highlights a recent dilutive equity raise at depressed stock levels as a key pressure point, which could signal value destruction in a nano-cap where capital decisions have outsized impact, even if the write-up frames it positively for liquidity.
Hi there, thanks for the great write up! I saw you mentioned "NMTC executed a $7 million equity raise, diluting existing shareholders" and was wondering if this could indicate management issuing equity at unduly depressed prices, potentially destroying shareholder value through poor capital allocation.
looks like it has a chance to be explosive.